Blog

Pune, June 9: Hyatt Regency Pune and Residences has announced the appointment of Gangaprasad Choudhari as Associate Director of Sales. With over 10 years of rich experience in hospitality sales, business development, and strategic account management, Gangaprasad brings with him deep industry expertise and a strong track record of driving business growth across  hospitality brands.

Prior to joining Hyatt Regency Pune, Gangaprasad was associated with Marriott International at Sheraton Grand Pune, where he served as Associate Director of Sales. In his role, he led proactive sales initiatives, managed key corporate and global accounts, and contributed significantly towards revenue generation across rooms and catering segments. His career journey also includes notable stints with Four Points by Sheraton Pune and Accor Hotels’ Novotel Pune and Novotel Imagica.

Recognized for his strengths in strategic sales leadership, RFP management, corporate contracting, and relationship building, Gangaprasad has consistently delivered impactful results in highly competitive markets. His expertise spans corporate, MICE, and leisure segments, making him a valuable addition to the leadership team at Hyatt Regency Pune.

Interestingly, Gangaprasad began his hospitality journey with Hyatt Hotels as a Food & Beverage Associate at Hyatt Regency Pune and was part of the hotel’s pre-opening team. His return to the property in a leadership capacity marks a significant milestone in his professional journey and reflects his longstanding association with the Hyatt brand.

In his new role, Gangaprasad will be responsible for strengthening the hotel’s sales strategy, expanding corporate partnerships, and driving overall business growth in alignment with Hyatt Regency Pune’s vision for excellence and market leadership.

Hyatt Regency Pune welcomes Gangaprasad back to the Hyatt family and looks forward to his contributions towards the hotel’s continued success.

Safaga, Egypt/ Abu Dhabi, UAE – 09 June 2026: AD Ports Group (ADX: ADPORTS), a leading global enabler of integrated trade, industry and logistics solutions, today launched trial operations at Noatum Ports – Safaga Terminal in Egypt ahead of the terminal’s full operational launch later this year.

His Excellency Lieutenant-General Eng. Kamel El Wazir, Minister of Transport – Egypt; and Captain Mohamed Juma Al Shamisi – Managing Director and Group CEO of AD Ports Group; along with senior officials have conducted a site tour of the new multipurpose terminal in Safaga Port – Egypt.

The officials reviewed the terminal’s operations, systems, and processes, which are designed to ensure full operational readiness and the seamless delivery of services in accordance with the highest international standards. The Noatum Ports – Safaga Terminal is being delivered under a 30-year concession agreement signed in 2023 for the development and operation of the multipurpose terminal, in partnership with Egypt’s Red Sea Ports Authority (RSPA).

Lieutenant General Engineer Kamel El-Wazir, Egypt’s Minister of Transport, said: “We commend the productive partnership with AD Ports Group to deliver a range of strategic maritime port projects along the Red Sea, as well as across various sectors of the maritime transport industry. Safaga Terminal serves as a key gateway for the development of Upper Egypt and will play a vital role in supporting the mining activities associated with the Golden Triangle Economic Zone, facilitating import and export operations, and enabling development projects across Northern, Central, and Southern Upper Egypt through enhanced connectivity with the port. This development is also expected to attract investments across industrial, logistics, warehousing, processing, and assembly sectors, while strengthening container and cargo transportation capabilities throughout the region, further supporting economic growth and trade development.” 

Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO – AD Ports Group, said: “Egypt is one of the Group’s most important international markets, and serves as a major trade gateway along the Group’s global network, spanning Asia, the Middle East, Africa, and South America. With strategic access to the Red Sea, Noatum Ports – Safaga Terminal reinforces our position as an enabler of trade across key waterways. We look forward to the full operational launch of our new terminal later this year, which represents another major step in our cooperation with our partners in Egypt, in line with the vision of our wise leadership.”

The Noatum Ports – Safaga Terminal will span approximately 810,000 m², featuring a 1,000-metre quay wall designed to handle up to 450,000 TEUs, alongside 5 million tonnes of dry bulk and general cargo, 1 million tonnes of liquid bulk, and 50,000 CEUs of Ro-Ro cargo.

The terminal is set to be the first internationally operated port terminal in the Upper Egypt region of southern Egypt, serving as a key gateway for the region and strengthening connectivity across Egypt, the Middle East, Africa, and global shipping routes.

Egypt and the Red Sea are a focus of AD Ports Group’s expanding global network of integrated trade, transport, and logistics facilities. In April 2026, Noatum Ports, the international ports operating arm of AD Ports Group confirmed the delivery of three new ship-to-shore (STS) and six rubber tyred gantry (RTG) cranes to its new multipurpose terminal in Safaga. Beyond its container feeder shipping and stevedoring services, the Group recently announced the commencement of cruise services at its three terminals in Sharm El Sheikh, Hurghada, and Safaga in Egypt, in addition to facilitating ferry services connecting Safaga and NEOM ports to support transport of Hajj workers between Egypt and Saudi Arabia. The Group is also developing the 20 km² KEZAD East Port Said Industrial and Logistics Park with Egyptian partners at the Mediterranean gateway of the Suez Canal.In November 2025, AD Ports Group invested 13.2 billion Egyptian pounds (USD 279 million) to acquire a 19.3% stake in one of Egypt’s largest container terminal operators, Alexandria Container & Cargo Handling Company (ALCN), and subsequently moved to acquire a majority stake in the company.

Mumbai, June 09th: Alkem Laboratories Ltd. today announced the launch of semaglutide in single–shot pre–filled syringes in multiple dose strengths.

Alkem is the first company in India to introduce semaglutide in single–shot pre–filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre–filled syringe format offers enhanced access, and convenience.

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre–filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

In March 2026, Alkem had already launched semaglutide in pre–filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.

Commenting on the development, Dr. Vikas Gupta, Chief Executive Officer, Alkem said, “Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre–filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy.”

Alkem remains committed to advancing high-quality, affordable medicines across key therapeutic areas and supporting better patient care in India.

Rockville, MD – Today, the American Society of Human Genetics (ASHG) announced the launch of the ASHG Artificial Intelligence (AI) Initiative, a multi-part effort designed to promote and advance the responsible, effective use of AI across human genetics and genomics. 

AI is rapidly transforming the ways scientists and clinicians interpret genomic data, improve diagnosis, advance personalized treatment strategies, and discover new therapeutic insights. Through this Initiative, ASHG will address the technical and ethical considerations of using AI in human genetics and genomics and create an actionable framework for how the human genetics and genomics community can harness AI and maximize its potential. This framework will provide recommendations for governance, standards, and ongoing education to enhance benefits for researchers, clinicians, and patients. 

“We are entering a new era in human genetics and genomics—accelerating discovery, sharpening interpretation, and expanding what’s possible in research and care,” said ASHG President Susan A. Slaugenhaupt, PhD. “This Initiative brings leaders together to tackle important questions about responsible use of AI in research and develop actionable recommendations that strengthen both scientific rigor and public confidence. Our goal is to help the global genetics and genomics community use this rapidly evolving technology responsibly so that we can analyze large data sets and foster scientific breakthroughs.”

The ASHG AI Initiative’s core components include: 

1. An invitation-only, in-person AI Summit that will bring together thought leaders from academia, government, and industry to address challenges and opportunities in governing and standardizing AI’s use in human genetics and genomics.
2. A two-day virtual symposium that will showcase cutting-edge research into the applications of AI in human genetics and genomics.
3. A published report with recommendations and outcomes from the summit and virtual symposium, as well as an actionable “roadmap for the future” that ASHG will use to advance the application and governance of AI in human genetics and genomics research. 

The ASHG AI Initiative Task Force, comprised of leaders in research, clinical genetics, and industry, will guide the initiative’s direction, shape convening agendas, and oversee the development of core deliverables. Marylyn Ritchie, PhD, Chief AI Officer at the Medical University of South Carolina chairs the task force which includes: Donavan Cheng, PhD (Ambry Genetics);  Eric Green, MD, PhD (Illumina); Stephanie Kraft, JD (Geisinger); Danielle Luz, MD (Stanford University School of Medicine); Ankit Malhotra, PhD (AWS); Natalie Pageler, MD (Stanford University School of Medicine); Robert Nussbaum, MD (University of California, San Francisco); Olga Troyanskya, PhD (Princeton University); Jennifer Wagner, JD, PhD (Pennsylvania State University); Nephi Walton, MD (University of Utah); and Kenny Wong, MS, CGC (xCures).

ASHG is grateful to Ambry Genetics and Amazon Web Services (AWS) for sponsoring and participating in this important initiative.